Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

173829

registered interest
date	14/01/2015
answering body	HM Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Public Expenditure
house id	1
legislature	25259 pref label House of Commons
question text	To ask Mr Chancellor of the Exchequer, how his Department defines non-fiscal spend.
tabling member constituency	Wakefield
tabling member printed	Mary Creagh
uin	220808
answer	answer is ministerial correction date of answer 21/01/2015 answer text “Non-fiscal spend” is not a formal term in the UK National Accounting framework. It is sometimes used to refer to items of public expenditure, which although included in departmental budgets, are either not classified as spending in the National Accounts or use a different source.<p> </p> answering member constituency Inverness, Nairn, Badenoch and Strathspey answering member printed Danny Alexander grouped question UIN 220622 220647 question first answered 21/01/2015 17:22:14 answering member 1535 label Biography information for Danny Alexander
tabling member	1579 label Biography information for Mary Creagh

173830

registered interest
date	14/01/2015
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	Sri Lanka
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign and Commonwealth Affairs, what recent assessment he has made of the political rights of and economic opportunities for Tamils in Sri Lanka.
tabling member constituency	Wycombe
tabling member printed	Steve Baker
uin	220697
answer	answer is ministerial correction date of answer 21/01/2015 answer text <p>The election of President Sirisena represents an opportunity for Sri Lanka to grow as a stable prosperous and inclusive country, reflecting the wishes of all of its people. The President’s 100 day programme and manifesto includes social, economic, educational and governance commitments that should benefit Tamil people. These include better access to education in the Tamil language; relief to displaced people; a democratic civil administration in the North and South of the island; bringing an end to racial and religious hatred; and, steps to promote reconciliation between communities.</p><p>We will be following the implementation of President Sirisena’s commitments closely, and stand ready to support Sri Lanka’s path to long term reconciliation.</p> answering member constituency East Devon answering member printed Mr Hugo Swire question first answered 21/01/2015 14:35:14 answering member 1408 label Biography information for Lord Swire
tabling member	4064 label Biography information for Mr Steve Baker

173836

registered interest
date	14/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund: Easington
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many patients in Easington constituency have accessed the Cancer Drugs Fund in each year since 2010.
tabling member constituency	Easington
tabling member printed	Grahame M. Morris
uin	220685
answer	answer is ministerial correction date of answer 20/01/2015 answer text <p>Prior to April 2013, information on the Cancer Drugs Fund was administered through clinical panels based in each strategic health authority (SHA) and data on the number of patients accessing the Fund at constituency level were not collected. Information for the North East SHA and England in 2010-11, 2011-12 and 2012-13 is shown below:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Number of patients<sup>1</sup> funded in</p><p>2010-11</p></td><td><p>Number of patients funded in<br> 2011-12</p></td><td><p>Number of patients funded in<br> 2012-13</p></td></tr><tr><td><p>North East SHA</p></td><td><p>420</p></td><td><p>696</p></td><td><p>526</p></td></tr><tr><td><p>England</p></td><td><p>2,780</p></td><td><p>11,798</p></td><td><p>15,456</p></td></tr></tbody></table><p> </p><p><em>Source:</em> Information provided to the Department by SHAs</p><p> </p><p><sup>1 </sup>Some individual patients may be double-counted where a patient has received more than one drug treatment through the Cancer Drugs Fund</p><p> </p><p> </p><p> </p><p>NHS England has had oversight of the Fund since April 2013 and publishes information on patient numbers routinely on its website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a></p><p> </p><p> </p><p> </p><p>Information for the NHS England North of England region and England in 2013-14 and 2014-15 (April- September) is shown below:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Number of patients<sup>1</sup> funded in</p><p>2013-14</p></td><td><p>Number of patients funded in<br> 2014-15</p><p>(April- September)</p></td></tr><tr><td><p>North of England, NHS England<sup>2</sup></p></td><td><p>5,327</p></td><td><p>3,027</p></td></tr><tr><td><p>England</p></td><td><p>19,560</p></td><td><p>11,308</p></td></tr></tbody></table><p> </p><p><em>Source:</em> NHS England</p><p> </p><p><sup>1 </sup>Some individual patients may be double-counted where a patient has received more than one drug treatment through the Cancer Drugs Fund</p><p> </p><p><sup>2 </sup>Includes individual cancer drugs fund request applications approved by the Cancer Drugs Fund panel in the North region</p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/01/2015 14:39:14 answering member 4020 label Biography information for George Freeman
tabling member	3973 label Biography information for Grahame Morris

173837

registered interest
date	14/01/2015
answering body	HM Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Offshore Industry: PAYE
house id	1
legislature	25259 pref label House of Commons
question text	To ask Mr Chancellor of the Exchequer, what recent representations he has received on the PAYE status of (a) divers and (b) diving supervisors working in the offshore energy industry.
tabling member constituency	Easington
tabling member printed	Grahame M. Morris
uin	220682
answer	answer is ministerial correction date of answer 21/01/2015 answer text The Chancellor receives a large variety of representations from a wide range of people.<p> </p> answering member constituency South West Hertfordshire answering member printed Mr David Gauke question first answered 21/01/2015 11:05:29 answering member 1529 label Biography information for Mr David Gauke
tabling member	3973 label Biography information for Grahame Morris

173838

registered interest
date	14/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had about extending the remit of the Cancer Drugs Fund to include access to other cancer treatments such as advanced stereotactic radiotherapy.
tabling member constituency	Easington
tabling member printed	Grahame M. Morris
uin	220683
answer	answer is ministerial correction date of answer 20/01/2015 answer text <p>We announced a £160 million boost to the Cancer Drugs Fund at the end of August 2014.</p><p> </p><p> </p><p> </p><p>NHS England announced on 12 January 2015 that it plans to increase the level of investment for drugs in the Cancer Drugs Fund from £280 million in 2014-15 to an expected £340 million in 2015-16.</p><p> </p><p> </p><p> </p><p>NHS England has also announced the extension of its Commissioning through the Evaluation programme to include stereotactic ablative radiotherapy (SABR). This will enable the number of cancer patients eligible to access SABR treatment to rise significantly, by 750 new patients a year and widen the number of cancers being treated.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/01/2015 14:56:08 answering member 4020 label Biography information for George Freeman
tabling member	3973 label Biography information for Grahame Morris

173839

registered interest
date	14/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Radiotherapy: Easington
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many patients in Easington constituency have received treatment using advanced stereotactic radiotherapy in each year since 2010.
tabling member constituency	Easington
tabling member printed	Grahame M. Morris
uin	220684
answer	answer is ministerial correction date of answer 21/01/2015 answer text <p>The information requested is shown in the following table.</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td colspan="6"><p>Finished Consultant Episodes (FCE)<sup>1</sup> with a Main or Secondary Operative Procedure<sup>2</sup> of stereotactic radiosurgery on the tissue of the brain, where the clinical commissioning group (CCG) of residence is Durham Dales, Easington and Sedgefield<sup>3</sup> for each of the last three years (2010-11 to 2012-13)<sup>4</sup></p></td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><p>Year</p></td><td><p>Count of FCEs</p></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><p>2010-11</p></td><td><p>9</p></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><p>2011-12</p></td><td><p>*</p></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><p>2012-13</p></td><td><p>8</p></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="5"><p><em>Source</em>: Hospital Episode Statistics (HES), Health and Social Care Information Centre</p></td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="6"><p>1 Finished Consultant Episode</p></td></tr><tr><td colspan="6"><p>A FCE is a continuous period of admitted patient care under one consultant within one healthcare provider. FCEs are counted against the year in which they end. Figures do not represent the number of different patients, as a person may have more than one episode of care within the same stay in hospital or in different stays in the same year.</p></td></tr><tr><td colspan="6"><p>2 Number of episodes with a main or secondary procedure</p></td></tr><tr><td colspan="6"><p>The number of episodes where the procedure (or intervention) was recorded in any of the 24 procedure fields in a Hospital Episode Statistics (HES) record. A record is only included once in each count, even if the procedure is recorded in more than one procedure field of the record. Note that more procedures are carried out than episodes with a main or secondary procedure. For example, patients undergoing a ‘cataract operation’ would tend to have at least two procedures – removal of the faulty lens and the fitting of a new one – counted in a single episode.</p><p>OPCS code used: A10.7 Stereotactic radiosurgery on tissue of the brain.</p></td></tr><tr><td colspan="6"><p> </p><p>3 CCG of residence</p></td></tr><tr><td colspan="6"><p>The CCG containing the patient’s normal home address. This does not necessarily reflect where the patient was treated as they may have travelled to another area for treatment.</p></td></tr><tr><td colspan="6"><p>4 Assessing growth through time (Inpatients)</p></td></tr><tr><td colspan="6"><p>Changes to the figures over time need to be interpreted in the context of improvements in data quality and coverage (particularly in earlier years), improvements in coverage of independent sector activity and changes in NHS practice. For example, changes in activity may be due to changes in the provision of care.</p></td></tr><tr><td colspan="6"><p>Small numbers</p></td></tr><tr><td colspan="6"><p>To protect patient confidentiality, figures between 1 and 5 have been replaced with “*” (an asterisk). Where it was still possible to identify figures from the total, additional figures have been replaced with &quot;*&quot;. Where the symbol &quot;-&quot; (dash) appears this represents the absence of data.</p><p>It should be noted that HES disclosure control rules only apply to 'known' values, e.g. small numbers where the age is unknown do not need to be replaced with &quot;*&quot;.</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/01/2015 16:02:06 answering member 3918 label Biography information for Jane Ellison
tabling member	3973 label Biography information for Grahame Morris

173840

registered interest
date	14/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Radiotherapy: North East
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had on improving access to advanced stereotactic radiotherapy for patients in the North East of England.
tabling member constituency	Easington
tabling member printed	Grahame M. Morris
uin	220686
answer	answer is ministerial correction date of answer 21/01/2015 answer text <p>My Rt. hon. Friend the Secretary of State meets NHS England regularly to discuss a wide range of issues, including access to cancer treatment.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/01/2015 15:56:27 answering member 3918 label Biography information for Jane Ellison
tabling member	3973 label Biography information for Grahame Morris

173841

registered interest
date	14/01/2015
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Transatlantic Trade and Investment Partnership
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what discussions he has had on how the Government will consult the public about the Transatlantic Trade and Investment Partnership.
tabling member constituency	Easington
tabling member printed	Grahame M. Morris
uin	220750
answer	answer is ministerial correction date of answer 27/01/2015 answer text <p>The Government regularly discusses the Transatlantic Trade and Investment Partnership with representatives from business, trade union, consumer and civil society groups. We will continue to seek to engage with all interested parties and provide information about the progress of discussions.</p><p> </p> answering member constituency West Suffolk answering member printed Matthew Hancock question first answered 27/01/2015 11:48:01 answering member 4070 label Biography information for Matt Hancock
tabling member	3973 label Biography information for Grahame Morris

173842

registered interest
date	14/01/2015
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Transatlantic Trade and Investment Partnership
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what assessment he has made of the potential economic costs and benefits of the Transatlantic Trade and Investment Partnership for the North East of England.
tabling member constituency	Easington
tabling member printed	Grahame M. Morris
uin	220751
answer	answer is ministerial correction date of answer 27/01/2015 answer text <p>The Transatlantic Trade and Investment Partnership could deliver a substantial economic boost for people living in the North East. For example the chemicals sector, which has a large presence in the region, could particularly benefit. Based on independent economic analysis, the Government estimates that the North East’s share of increased exports could be up to £1.05 billion.</p><p> </p> answering member constituency West Suffolk answering member printed Matthew Hancock question first answered 27/01/2015 11:46:14 answering member 4070 label Biography information for Matt Hancock
tabling member	3973 label Biography information for Grahame Morris

173843

registered interest
date	14/01/2015
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Transatlantic Trade and Investment Partnership
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, which organisations he has consulted on the negotiations on the Transatlantic Trade and Investment Partnership.
tabling member constituency	Easington
tabling member printed	Grahame M. Morris
uin	220752
answer	answer is ministerial correction date of answer 27/01/2015 answer text <p>The Government is committed to full and effective consultation on the Transatlantic Trade and Investment Partnership and has discussed it with a broad range of stakeholders across the UK. Organisations consulted include business representative bodies, such as the CBI and the Federation of Small Business, and trades unions including the TUC, Unison, the GMB and others. We have also regularly consulted Which? to discuss the potential benefits to consumers and of a coalition of civil society campaigners, including the Trade Justice Movement, Friends of the Earth, War on Want and the World Development Movement.</p><p> </p> answering member constituency West Suffolk answering member printed Matthew Hancock question first answered 27/01/2015 11:48:59 answering member 4070 label Biography information for Matt Hancock
tabling member	3973 label Biography information for Grahame Morris